Hamilton Health Sciences

Running trials

• Recruiting

  Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

  NCT07245394· Source

• Recruiting

  Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

  NCT07272902· Source

• Recruiting

  Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

  NCT07175428· Phase 2· Source

• Recruiting

  Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis

  NCT06660693· Phase 3· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Source

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Source

• Recruiting

  Pericardiotomy in Cardiac Surgery

  NCT06486636· Source

• Recruiting

  RAFT - Pace &Ablate

  NCT06299514· Source

• Recruiting

  COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

  NCT05873881· Phase 3· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

  NCT05987449· Phase 1/2· Source

• Recruiting

  Left vs Left Randomized Clinical Trial

  NCT05650658· Source

• Recruiting

  A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

  NCT05495906· Phase 4· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Source

• Active, not recruiting

  Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  NCT05445778· Phase 3· Source

• Recruiting

  Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation

  NCT05511389· Source

• Active, not recruiting

  Clinical Trial on Agitation in Alzheimer's Dementia

  NCT05543681· Phase 2· Source

• Recruiting

  Screening Donors, Fecal Microbiota Transplant Program in Ulcerative Colitis

  NCT04926103· Source

• Active, not recruiting

  A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

  NCT05181618· Phase 4· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Source

• Active, not recruiting

  COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

  NCT05333068· Source

• Recruiting

  CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  NCT05267886· Phase 4· Source

• Recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04910568· Phase 1· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04961567· Phase 3· Source

• Recruiting

  Nabilone for Agitation Blinded Intervention Trial

  NCT04516057· Phase 3· Source

• Recruiting

  Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

  NCT04634240· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

  NCT04370054· Phase 3· Source

• Active, not recruiting

  SELUTION SLR™ 014 In-stent Restenosis

  NCT04280029· Source

• Active, not recruiting

  Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

  NCT03947619· Source

• Enrolling by invitation

  A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

  NCT03745924· Source

• Active, not recruiting

  LEADERS FREE II: BioFreedom™ Pivotal Study

  NCT02843633· Source

• Recruiting

  The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN)

  NCT02308917· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation5 recruiting
• Heart failure4 recruiting
• Ulcerative colitis4 recruiting
• Stroke3 recruiting
• Haemophilia2 recruiting
• Alzheimer disease1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• HIV1 recruiting
• Lung cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Terminated

  Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

  NCT05605678· Source

• Completed

  IBD Neoplasia Surveillance RCT

  NCT05809999· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis

  NCT04231110· Phase 4· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Source

• Completed

  Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

  NCT04223778· Phase 3· Source

• Completed

  Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

  NCT04223791· Phase 3· Source

• Completed

  EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  NCT03950076· Phase 4· Source

• Completed

  Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

  NCT03982394· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· Source

• Terminated

  Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

  NCT02387229· Phase 3· Source

• Withdrawn

  Improving Outcomes After Time Sensitive Prehospital Interventions: Rescu Epistry

  NCT04110912· Source

• Completed

  Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation

  NCT01994252· Source

• Completed

  Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

  NCT01842568· Source

Trial sites

• 1240065 - Hamilton Health Sciences1 trial
• Geras Centre for Aging Research, Hamilton Health Sciences1 trial
• Hamilton Health Science1 trial
• Hamilton Health Sciences20 trials
• Hamilton Health Sciences Corp1 trial
• Hamilton Health Sciences Corp, Ontario1 trial
• Hamilton Health Sciences Corporation11 trials
• Hamilton Health Sciences Corporation /ID# 2140531 trial
• Hamilton Health Sciences - General Site1 trial
• Hamilton Health Sciences (HHS)1 trial
• Hamilton Health Sciences - Juravinski Site (Site 0106)1 trial
• Hamilton Health Sciences - Juravinski Site (Site 1104)1 trial
• Hamilton Health Sciences , Mcmaster University2 trials
• Hamilton Health Sciences (Site 1103)1 trial
• Hamilton Health Sciences (Site 2803)1 trial
• Juravinski Cancer Centre - Hamilton Health Sciences /ID# 2693961 trial
• MUMC - Hamilton Health Sciences1 trial